ABBV-969 is a dual variable domain IgG1 drug conjugate comprising PSMA and STEAP1 binding domains and a topoisomerase 1 inhibitor (Top1i) payload. Based on preclinical and clinical data of other Top1i ADCs, ABBV-969 is expected to have improved efficacy and broader breadth of activity vs targeting either antigen alone.

ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 140 adult participants will be enrolled in the study across sites worldwide.

2024年12月31日 · • ABBV-969是一种双变量免疫球蛋白G1抗体偶联药物，包含PSMA和STEAP1结合域以及拓扑异构酶1抑制剂作为杀伤肿瘤细胞的payload. • ABBV-969预计将比单独针对任一抗原的药物具有更好的疗效和更广泛的活性范围. • 可获得代表性的基线肿瘤组织（任何NHA和/或任何PSMA靶向治疗后最近的存档肿瘤组织或筛选阶段收集的新鲜活检组织）适合进行IHC检测。 此要求可由AbbVie医学监察官酌情豁免. 平台声明：该文观点仅代表作者本人，搜 …

ABBV-969 is a dual variable domain IgG1 drug gens and actionable targets in conjugate comprising PSMA and STEAP1 binding domains and a topoisomerase 1 inhibitor (Top1i) payload.

ABBV-969 is a dual variable domain IgG1 drug conjugate comprising PSMA and STEAP1 binding domains and a topoisomerase 1 inhibitor (Top1i) payload. Based on preclinical and clinical data of other Top1i ADCs, ABBV-969 is expected to have improved efficacy and broader breadth of activity vs targeting either antigen alone.We describe a rst-in-human ...

Upon administration of anti-PSMA/STEAP1 ADC ABBV-969, the antibody moiety targets and binds to PSMA and STEAP1 expressed on tumor cells. Following receptor internalization, the cytotoxic payload is released and induces tumor cell death through an as of yet unknown mechanism of action.

ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 140 adult participants will be enrolled in the study across sites worldwide.

2024年11月25日 · ABBV-969是AbbVie公司开发的一款靶向PSMA和STEAP1的抗体药物偶联物，具有拓扑异构酶1抑制剂（Top1i）有效负载。 用于治疗转移性去势抵抗性前列腺癌，目前处于临床1期研究阶段。

The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy. ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2024) - P1 | "Pts will be enrolled in US, Israel, Japan, and Australia in part 1; additional locations may be added.